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ABSTRACT
Non-tuberculous mycobacteria (NTM) are ubiquitous
environmental organisms that can cause chronic
pulmonary infection, particularly in individuals with pre-
existing inflammatory lung disease such as cystic fibrosis
(CF). Pulmonary disease caused by NTM has emerged as
a major threat to the health of individuals with CF but
remains difficult to diagnose and problematic to treat. In
response to this challenge, the US Cystic Fibrosis
Foundation (CFF) and the European Cystic Fibrosis
Society (ECFS) convened an expert panel of specialists to
develop consensus recommendations for the screening,
investigation, diagnosis and management of NTM
pulmonary disease in individuals with CF. Nineteen
experts were invited to participate in the
recommendation development process. Population,
Intervention, Comparison, Outcome (PICO) methodology
and systematic literature reviews were employed to
inform draft recommendations. An anonymous voting
process was used by the committee to reach consensus.
All committee members were asked to rate each
statement on a scale of: 0, completely disagree, to 9,
completely agree; with 80% or more of scores between
7 and 9 being considered ‘good’ agreement.
Additionally, the committee solicited feedback from the
CF communities in the USA and Europe and considered
the feedback in the development of the final
recommendation statements. Three rounds of voting
were conducted to achieve 80% consensus for each
recommendation statement. Through this process, we
have generated a series of pragmatic, evidence-based
recommendations for the screening, investigation,
diagnosis and treatment of NTM infection in individuals
with CF as an initial step in optimising management for
this challenging condition.
BACKGROUND
Epidemiology of non-tuberculous mycobacteria
in individuals with cystic fibrosis
Non-tuberculous mycobacteria (NTM) are increas-
ingly being isolated from the sputum of adults and
children with cystic fibrosis (CF), both in North
America and in Europe.1–17 Estimates of the preva-
lence of NTM in the CF population have ranged
from 1.3% in the earliest study reported in 19841
to 32.7% in a review of individuals with CF over
the age of 40 years in Colorado.9 To date, the
largest studies published examined 986,6 121615
and 158217 individuals with CF and reported rates
of NTM-positive cultures of 13.0%, 13.7% and
6.6%, respectively. Recently, analysis of US Cystic
Fibrosis Foundation (CFF) registry data has shown
prevalence rates for NTM-positive culture in the
USA of 12%18 but with considerable variation
between individual states (0–28%).19
The NTM species most commonly identified in
individuals with CF from North America and Europe
are the slow-growing Mycobacterium avium complex
(MAC) (including M. avium, M. intracellulare and M.
chimaera), which can be found in up to 72% of
NTM-positive sputum cultures,6 and the rapid-
growing M. abscessus complex (MABSC) (comprising
the subspecies M. abscessus subsp abscessus
(M. a. abscessus), M. a. bolletii20 and
M. a. massiliense21 22 (the latter currently classified as
part ofM. a. bolletii)), which in many centres has now
become the most common NTM isolated from indivi-
duals with CF.7 15 17 21 23–25 Other less commonly
isolated species include M. simiae,11 M. kansasii and
M. fortuitum.26 There are geographical differences in
both the prevalence of NTM-positive cultures and
also the relative frequency of different species seen
between but also within countries.6 17 19 24 25 27
NTM acquisition is strongly associated with age
in individuals with CF, with prevalence increasing
from 10% in children aged 10 years, to over 30%
in adults over the age of 40 years.9 In individuals
with an adult diagnosis of CF, over 50% (mostly
females) have NTM-positive airway cultures.9
There appear to be species-specific differences in
age-related prevalence within CF cohorts, with
MAC more commonly isolated from adults over
25 years of age,6 7 14 17 27 while MABSC is iso-
lated from all age groups, but peaks between
those 11 and 15 years of age in some studies.17 28
There may also be species-specific differences in
virulence: individuals with MABSC-positive
cultures are more likely to meet American
Thoracic Society (ATS)/Infectious Diseases Society
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of America (IDSA) criteria for diagnosing NTM pulmonary
disease (NTM-PD, see Diagnosis of NTM-PD in CF section),
and have worse morbidity and mortality associated with a
more rapid decline in lung function.15 27 29 30
There has been a rise over the last four decades in the
reported prevalence of NTM-positive cultures in respiratory
samples from individuals with CF,1 6 15 17 18 23 an increase
in part mirroring temporal changes seen in the non-CF
cohort.31–38 While increasing detection rates may reflect
enhanced surveillance and/or improved microbiological detec-
tion,6 27 39–42 there are a number of lines of evidence
suggesting a true rise in the frequency of NTM infection.
A number of CF studies43 show year on year increases in
NTM-positive cultures with no change in surveillance inten-
sity or culture methodology. There has been an increase over
time in rates of skin test reactivity to NTM antigens in US
population-based testing studies,44 potentially indicating
increasing exposure to NTM (see below). Furthermore, the
relative frequency of M. abscessus detection in NTM-positive
samples from individuals with CF has increased remarkably
over time both in the USA and in Europe,2 6 15 17 23 27 sug-
gesting real changes in NTM acquisition rates (rather than
increased sampling).
Possible reasons for the potential increased frequency of
NTM-positive cultures in individuals with CF include: increases
in environmental exposure to NTM through more permissive
temperature settings of home water heaters45 and more contact
with shower aerosols,46 47 increased antibiotic usage creating
more NTM favourable lung niches,27 greater chronic use of
medications that might impair host immunity to NTM,43 and/or
spread of NTM through person-to-person transmission.48 49
NTM-PD in individuals with CF
NTM can cause progressive inflammatory lung damage, a condi-
tion termed ‘NTM pulmonary disease’ (NTM-PD),50 51 which
is defined by the presence of specific microbiological, clinical
and radiological features described in Diagnosis of NTM-PD in
CF section. However, it has become clear that NTM can also
transiently, intermittently or permanently reside within the
lungs of individuals with CF without causing NTM-PD, thus
representing asymptomatic infection and creating considerable
difficulties in deciding how best to screen for and diagnose
NTM.30 Further challenges exist in knowing how best to iden-
tify NTM in respiratory samples, when and how to initiate treat-
ment for NTM-PD (as highlighted by a recent Cochrane
review52) and how NTM may impact individuals under consid-
eration for lung transplantation. As a consequence, the CFF and
European Cystic Fibrosis Society (ECFS) sought to generate a
consensus recommendations document to support and standard-
ise the management of NTM infection in individuals with CF,
permitting prospective evaluation of current best practice and
forming a foundation for future research programmes.
These consensus statements have been developed to assist in the
management both of adults and children with CF who are infected
with NTM. Given the virtual absence of published evidence to
guide paediatric care,53 recommendations for children with CF
infected with NTM are based on extrapolated adult data, the prac-
tical experience of experts and appropriate adjustment of drug
regimens, and are, except where stated, the same as for adults.
METHODS
Expert committee structure
The CFF and the ECFS invited experts to participate in the
statement development process. The 19-member committee
consisted of professionals (10 US and 9 European) with expert-
ise in CF and NTM, and included adult and paediatric CF phy-
sicians, lung transplant physicians, microbiologists, infectious
disease specialists and a parent of an individual with CF. The
committee convened in May 2012 and was divided into five
subgroups, each responsible for a specific topic: Epidemiology
and Risk Factors, Screening, Microbiology, Treatment and
Transplantation. Each subgroup developed topic-specific ques-
tions using the PICO format (Population, Intervention,
Comparison, Outcome.54) Questions were reviewed and
approved by the entire committee before systematic literature
searches were conducted.
Review process and consensus vote
The members of each subgroup used the PICO questions to
guide literature searches in PubMed. Searches were limited to
the English language and the period 1984 to 2013. Subgroup
members also searched for topic-relevant guidelines through
searches of the ATS website, the IDSA website, the Clinical
Laboratory Standards Institute (CLSI) website and the UK CF
Trust website.
After reviewing the relevant literature and existing guidelines,
subgroup members drafted recommendation statements. In
October 2012, a second meeting was convened and subgroups
finalised draft recommendation statements. The committee also
voted to set 80% agreement of all 19 members as the threshold
for acceptance of a recommendation statement and not to use
the GRADE system of evaluating published evidence, given the
paucity of clinical trial data.
Each subgroup submitted final draft questions for entry into
an electronic survey tool (Survey Monkey) for the purposes of
anonymous voting and comment by all members. A project
coordinator administered the survey and committee members
were asked to rate each statement on a scale of: 0, completely
disagree, to 9, completely agree; with 80% or between 7 and 9
being considered ‘good’ agreement. Space for entering free text
was also provided after each statement to allow members to cite
literature in support of their opinions or suggested revisions. All
committee members were required to vote on each statement
regardless of their role or expertise. Multiple rounds of voting
and revisions to the statements were conducted, and for each
round committee members were requested to complete their
voting within 3 weeks. The committee chairs reviewed the
results from each round and updated the statements based on
comments entered by respondents for subsequent rounds.
External review
A draft of the recommendations was presented at the 2013
North American Cystic Fibrosis Conference and the European
Cystic Fibrosis Society Meeting. Additionally, the committee
solicited feedback from the CF communities in the USA and in
Europe, which included physicians, nurses, physical and respira-
tory therapists, parents and individuals with CF. All comments
collected from this process were reviewed and addressed by the
committee in the development of the final recommendation
statements.
RESULTS
Final recommendations and results of the consensus vote
Three rounds of voting were conducted to achieve 80% consen-
sus for each statement. Fifty-three statements were included in
the first round of voting and 50 statements in the second and
third rounds. Final statements and the consensus are reported in
table 1.
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Table 1 NTM recommendation statements
Recommendation Consensus (%)
Recommendation 1: The CF Foundation and the ECFS recommend that the potential for cross-infection of NTM (particularly Mycobacterium abscessus
complex) between individuals with CF should be minimised by following national infection control guidelines
94
Recommendation 2: The CF Foundation and the ECFS recommend that cultures for NTM be performed annually in spontaneously expectorating individuals
with a stable clinical course
94
Recommendation 3: The CF Foundation and the ECFS recommend that, in the absence of clinical features suggestive of NTM pulmonary disease,
individuals who are not capable of spontaneously producing sputum do not require screening cultures for NTM
100
Recommendation 4: The CF Foundation and the ECFS recommend that culture and smears for AFB from sputum should be used for NTM screening 100
Recommendation 5: The CF Foundation and the ECFS recommend against the use of oropharyngeal swabs for NTM screening 100
Recommendation 6: The CF Foundation and the ECFS recommend that culture and smears for AFB from sputum, induced sputum, bronchial washings or
bronchoalveolar lavage samples can be used to evaluate individuals with CF suspected to have NTM pulmonary disease.
100
Recommendation 7: The CF Foundation and the ECFS recommend against the routine use of transbronchial biopsies to detect NTM in individuals with CF
suspected to have NTM pulmonary disease
100
Recommendation 8: The CF Foundation and the ECFS recommend against the use of oropharyngeal swabs to perform diagnostic smears and cultures in
individuals with CF suspected to have NTM pulmonary disease
100
Recommendation 9: The CF Foundation and the ECFS recommend that respiratory tract samples should be cultured using both solid and liquid media 100
Recommendation 10: The CF Foundation and the ECFS recommend that the incubation duration for NTM cultures should be for a minimum of 6 weeks 100
Recommendation 11: The CF Foundation and the ECFS recommend that an NTM culture should be processed within 24 h of collection to optimise the
detection of NTM in respiratory samples. If a delay in processing is anticipated, refrigeration of samples is advised
100
Recommendation 12: The CF Foundation and the ECFS recommend that respiratory tract samples should be decontaminated using the standard N-acetyl
L-cysteine, NALC, (0.5%)–NaOH (2%) method
100
Recommendation 13: The CF Foundation and the ECFS recommend that, if a sample remains contaminated with Gram-negative bacteria after standard
NALC-NaOH decontamination, it should be further treated with either 5% oxalic acid or 1% chlorhexidine
100
Recommendation 14: The CF Foundation and the ECFS recommend against the use of non-culture-based methods for detecting NTM in respiratory tract
samples
100
Recommendation 15: The CF Foundation and the ECFS recommend that all NTM isolates from individuals with CF should undergo molecular identification 100
Recommendation 16: The CF Foundation and the ECFS recommend that all NTM isolates from individuals with CF should be identified to the species level,
except for M. intracellulare, M. avium and M. chimaera, where identification can be limited to MAC, and M. abscessus complex, which should be
subspeciated
83
Recommendation 17: The CF Foundation and the ECFS recommend that for MAC, clarithromycin susceptibility testing should be performed on an isolate
recovered prior to initiation of treatment. Clarithromycin susceptibility testing should also be performed on subsequent isolates if the patient (a) fails to
culture convert after 6 months of NTM treatment; (b) recultures MAC after initial culture conversion while on NTM treatment or (c) recultures MAC after
completion of NTM treatment
94
Recommendation 18: The CF Foundation and the ECFS recommend that for M. abscessus complex, susceptibility testing should include at least
clarithromycin, cefoxitin and amikacin (and preferably also tigecycline, imipenem, minocycline, moxifloxacin and linezolid)
89
Recommendation 19: The CF Foundation and the ECFS recommend that drug susceptibility testing should be performed in accordance with CLSI guidelines 100
Recommendation 20: The CF Foundation and the ECFS recommend that ATS/IDSA criteria for the diagnosis of NTM pulmonary disease should be used in
individuals with CF (ATS/IDSA 2007 Statement)
100
Recommendation 21: The CF Foundation and the ECFS recommend that other CF pathogens and comorbidities should be considered as potential
contributors to a patient’s symptoms and radiological features when determining the clinical significance of NTM-positive cultures
100
Recommendation 22: The CF Foundation and the ECFS recommend that NTM treatment should be considered for individuals with CF who have ATS/IDSA
defined NTM pulmonary disease
100
Recommendation 23: The CF Foundation and the ECFS recommend that individuals receiving azithromycin as part of their CF medical regimen who have a
positive NTM culture should not continue azithromycin treatment while evaluation for NTM disease is underway as azithromycin monotherapy may lead to
resistance. A macrolide agent may be included in a multidrug treatment regimen if criteria are met for NTM disease
89
Recommendation 24: The CF Foundation and the ECFS recommend that treatment of M. abscessus complex pulmonary disease should involve an intensive
phase followed by a continuation phase
100
Recommendation 25: The CF Foundation and the ECFS recommend that the intensive phase should include a daily oral macrolide (preferably azithromycin)
in conjunction with 3–12 weeks of intravenous amikacin and one or more of the following: intravenous tigecycline, imipenem or cefoxitin, guided but not
dictated by drug susceptibility testing. The duration of intensive phase therapy should be determined by the severity of infection, the response to
treatment and the tolerability of the regimen
83
Recommendation 26: The CF Foundation and the ECFS recommend that the continuation phase should include a daily oral macrolide (preferably
azithromycin) and inhaled amikacin, in conjunction with 2–3 of the following additional oral antibiotics: minocycline, clofazimine, moxifloxacin and
linezolid, guided but not dictated by drug susceptibility testing
89
Recommendation 27: The CF Foundation and the ECFS recommend that individuals with M. abscessus complex pulmonary disease should be managed in
collaboration with experts in the treatment of NTM and CF, as drug intolerance and drug-related toxicity occur frequently, and changes in antibiotic
therapy are often required
89
Recommendation 28: The CF Foundation and the ECFS recommend that monotherapy with a macrolide or other antimicrobial should never be used in the
treatment of M. abscessus complex pulmonary disease
100
Recommendation 29: The CF Foundation and the ECFS recommend the same antibiotic regimen for treatment of all species within the MAC 94
Recommendation 30: The CF Foundation and the ECFS recommend that clarithromycin-sensitive MAC pulmonary disease should be treated with a daily
oral antibiotic regimen containing a macrolide (preferably azithromycin), rifampin and ethambutol
89
Recommendation 31: The CF Foundation and the ECFS recommend against the use of intermittent (three times per week) oral antibiotic therapy to treat
MAC pulmonary disease
89
Recommendation 32: The CF Foundation and the ECFS recommend that monotherapy with a macrolide or other antimicrobial agent should never be used
in the treatment of MAC pulmonary disease
100
Continued
Floto RA, et al. Thorax 2016;71:1–22. doi:10.1136/thoraxjnl-2015-207360 i3
Supplement
RISK FACTORS
Are there modifiable risk factors for the development
of NTM-PD in individuals with CF?
Recommendation 1: The CF Foundation and the ECFS recom-
mend that the potential for cross-infection of NTM (particu-
larly MABSC) between individuals with CF should be
minimised by following national infection control guidelines.
CF-related lung disease is a clear risk factor for the development
of NTM-PD and is presumed to relate to the presence of struc-
tural lung damage, impaired mucociliary clearance and inflamed
airways; all of which are thought to favour the development of
chronic NTM infection.55 Cystic Fibrosis Transmembrane con-
ductance Regulator (CFTR) dysfunction may, of itself, predis-
pose to NTM infection (although the pathophysiology is
unknown), since rates of heterozygosity for CFTR mutations
within the non-CF population with pulmonary NTM disease
are high (30–50%).56 57
However, other risk factors that predispose specific indivi-
duals with CF to acquire NTM or to develop NTM-PD are, for
the most part, poorly understood, with many studies presenting
conflicting results. Potential risk factors for NTM acquisition
are listed below.
Lung function
There have been conflicting reports on whether an individual’s
spirometry results are related to the likelihood of finding
NTM-positive samples, with some studies suggesting no associ-
ation with lung function,13 a positive association of NTM acqui-
sition with higher FEV1% predicted
6 or, conversely, with worse
lung function.11 15 30 Support for the possibility that NTM
acquisition is more likely in CF individuals with severe lung
disease comes from observations that the prevalence of
NTM-positive sputum samples in patients referred for lung
transplantation has been reported to be as high as 19.7%.29
Lung infection with specific pathogens
In some studies, individuals with CF with NTM-positive
samples are more likely to have Staphylococcus aureus infection
Table 1 Continued
Recommendation Consensus (%)
Recommendation 33: The CF Foundation and the ECFS recommend that an initial course of intravenous amikacin should be considered for the treatment
of MAC pulmonary disease in the presence of one or more of the following:
i. AFB smear positive respiratory tract samples
ii. Radiological evidence of lung cavitation or severe infection
iii. Systemic signs of illness
94
Recommendation 34: The CF Foundation and the ECFS recommend that clarithromycin-resistant MAC pulmonary disease should be managed in
collaboration with experts in the treatment of NTM and CF
89
Recommendation 35: The CF Foundation and the ECFS recommend that individuals with CF receiving NTM treatment should have expectorated or induced
sputum samples sent for NTM culture every 4–8 weeks throughout the entire course of treatment to assess the microbiological response
94
Recommendation 36: The CF Foundation and the ECFS recommend that a schedule for detecting drug toxicity (including hearing loss, visual loss, renal
impairment and liver function test abnormalities) should be set in place at the time of NTM treatment initiation and implemented throughout treatment
based on the specific drugs prescribed
100
Recommendation 37: The CF Foundation and the ECFS recommend that an HRCT scan of the lungs should be performed shortly before starting NTM
treatment and at the end of NTM treatment to assess the radiological response
94
Recommendation 38: The CF Foundation and the ECFS recommend that NTM antibiotic therapy should be prescribed for 12 months beyond culture
conversion (defined as three consecutive negative cultures, with the time of conversion being the date of the first of the three negative cultures) as long
as no positive cultures are obtained during those 12 months
94
Recommendation 39: The CF Foundation and the ECFS recommend that individuals who fail to culture convert despite optimal NTM therapy may benefit
from long-term suppressive antibiotic treatment
94
Recommendation 40: The CF Foundation and the ECFS recommend that, when amikacin is given intravenously or when streptomycin is given intravenously
or intramuscularly, serum levels should be monitored and dosing adjusted to minimise ototoxicity and nephrotoxicity
100
Recommendation 41: The CF Foundation and the ECFS recommend against routinely obtaining serum levels of other anti-mycobacterial drugs. However,
absorption of oral medications is often reduced in CF. Therefore use of therapeutic drug monitoring should be considered for individuals failing to improve
despite taking recommended drug regimens or for those on concomitant medications with significant interactions with NTM drugs
100
Recommendation 42: The CF Foundation and the ECFS recommend against the use of interferon γ as adjuvant therapy for NTM pulmonary disease in
individuals with CF
89
Recommendation 43: The CF Foundation and the ECFS recommend that vitamin D should be supplemented according to national CF care guidelines 94
Recommendation 44: The CF Foundation and the ECFS recommend that lung resection should only be considered under extraordinary circumstances and in
consultation with experts on the treatment of NTM and CF
83
Recommendation 45: The CF Foundation and the ECFS recommend that all individuals with CF being considered for lung transplantation should be
evaluated for NTM pulmonary disease
100
Recommendation 46: The CF Foundation and the ECFS recommend that the presence of current or previous respiratory tract samples positive for NTM
should not preclude individuals being considered for lung transplantation
94
Recommendation 47: The CF Foundation and the ECFS recommend that individuals with CF who have NTM pulmonary disease and are being evaluated
for transplantation should start treatment prior to transplant listing
100
Recommendation 48: The CF Foundation and the ECFS recommend that individuals with CF receiving NTM treatment with sequential negative cultures
may be eligible for transplant listing
100
Recommendation 49: The CF Foundation and the ECFS recommend that individuals with CF who have completed treatment for NTM pulmonary disease
with apparent eradication of the organism may be eligible for transplant listing
100
Recommendation 50: The CF Foundation and the ECFS recommend that the presence of persistent M. abscessus complex or MAC infection despite optimal
therapy is not an absolute contraindication to lung transplant referral
94
AFB, acid-fast bacilli; CF, cystic fibrosis; CLSI, Clinical Laboratory Standards Institute; ECFS, European Cystic Fibrosis Society; HRCT, High-resolution CT; MAC, M. avium complex;
NTM, non-tuberculous mycobacteria.
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and less likely to have Pseudomonas aeruginosa chronic pulmon-
ary infection.6 7 58 Other studies, however, have reported NTM
positivity associated with higher rates of P. aeruginosa infec-
tion,11 and variably associated with S. maltophilia infection.6 58
In contrast, Aspergillus fumigatus has consistently been asso-
ciated with the presence of NTM-positive cultures,11 15 59 with
some reports indicating an association with allergic bronchopul-
monary aspergillosis.7 27 60
Medications
Corticosteroids
The impact of systemic steroids on NTM acquisition is contro-
versial. There have been suggestions that steroids may protect
against58 or predispose towards NTM infection,60 or may not
influence the risk of NTM acquisition.4 11 12 Recent data from
non-CF populations, however, have suggested that oral as well
as some types of inhaled corticosteroids are associated with
increased risk of NTM acquisition.61–63
Proton pump inhibitors
The impact of proton pump inhibitor (PPI) is unclear. PPI use
has been reported to be associated with the development of
MAC pulmonary disease in non-CF cohorts,64 and may
promote gastrointestinal survival of NTM and subsequent lung
infection through gastric aspiration.
Azithromycin
Particular attention has recently been paid to the role of long-
term azithromycin use as a risk factor for the acquisition of
NTM. In a single centre study of CF adults, Renna et al43
reported increases in annual rates of NTM infection associated
with chronic azithromycin use, postulating, through in vitro
studies and mouse infection models, that azithromycin blocked
autophagic killing of NTM within macrophages. While sup-
porting findings from a previous case–control study reporting
increased azithromycin use in individuals with NTM,11 other
large retrospective studies have shown no such associ-
ation.12 13 59 65–67 This includes a recent nested case–control
analysis within the CF registry, which suggested long-term azi-
thromycin use may protect against infection with NTM.67
Acquisition of NTM through cross-infection
Person-to-person transmission of NTM has traditionally been
considered unlikely. Two separate studies have shown that
patients, even siblings living in the same household for more
than 10 years, have unique strains,7 68 suggesting a lack of
person-to-person transmission. However, a case report from the
University of Washington described a possible outbreak of
M. a. massiliense in five patients48 with potential transmission
occurring during synchronous clinic visits. Recently, whole
genome sequencing and antimicrobial susceptibility testing per-
formed on 168 consecutive isolates of M. abscessus from 31
patients attending an adult CF centre in the UK revealed fre-
quent, probably indirect, transmission of M. a. massiliense
between individuals with CF despite conventional cross-
infection measures.69 The results of these studies indicate that
cross-infection may be an important mechanism for the acquisi-
tion of M. abscessus (at least within the CF population). To
date, there has been no published evidence suggesting
person-to-person transmission of other NTM species.
Other factors extrapolated from data in non-CF populations
or studies on M. tuberculosis that might contribute to NTM
acquisition in individuals with CF include: low vitamin D,70 71
the presence of gastro-oesophageal reflux disease,64 72 low body
mass index56 73 or malnutrition.74
SCREENING
How often should individuals with CF be screened for NTM?
Recommendation 2: The CF Foundation and the ECFS recom-
mend that cultures for NTM be performed annually in spontan-
eously expectorating individuals with a stable clinical course.
Recommendation 3: The CF Foundation and the ECFS rec-
ommend that, in the absence of clinical features suggestive of
NTM-PD, individuals who are not capable of spontaneously
producing sputum do not require screening cultures for NTM.
Over the past two decades, a number of expert opinions and
reviews have urged routine screening for NTM in the general
CF population. However, the optimal frequency and methodo-
logy for NTM surveillance in individuals with CF are not
known. NTM are common in the environment, and are likely
to be transiently introduced on a regular basis into the airways
of individuals with CF. More frequent screening will, therefore,
result in detection of more positive cultures,11 many of which
will not be associated with the presence of NTM-PD,6 30 58 gen-
erating anxiety in patients and caregivers and initiating further
(potentially invasive) investigations. However, signs and symp-
toms of NTM disease are often subtle and non-specific, and the
diagnosis can be delayed for years or missed altogether in the
absence of effective surveillance.4 Furthermore, systematic
screening may help researchers more accurately identify factors
influencing poorly understood host susceptibility, acquisition,
transmission and virulence of NTM. It is important to empha-
sise that screening refers to obtaining samples from individuals
with no clinical, microbiological or radiological suspicion of
NTM infection, and should be distinguished from strategies to
investigate and diagnose NTM disease (covered in Diagnosis of
NTM-PD in CF section).
While our understanding of those factors predisposing indivi-
duals with CF to NTM infection is incomplete, there is, never-
theless, agreement that certain patient populations are at greater
risk and therefore probably require more frequent surveillance.
These populations include: those with advanced lung disease
and previous NTM-positive cultures, and those living in areas
with high NTM prevalence. Conversely, in individuals with no
recognised risk factors, the prevalence of NTM infection is
likely to be low; thus less frequent, perhaps annual, surveillance
is warranted. In addition, NTM screening is important before
starting long-term azithromycin treatment to avoid inadvertent
macrolide monotherapy in individuals with undiagnosed NTM
infection (in keeping with published guidelines.75)
How should screening for NTM be performed?
Recommendation 4: The CF Foundation and the ECFS recom-
mend that culture and smears for acid-fast bacilli (AFB) from
sputum should be used for NTM screening.
Recommendation 5: The CF Foundation and the ECFS rec-
ommend against the use of oropharyngeal swabs for NTM
screening.
The majority of published reports describing the prevalence of
NTM in the CF population utilised AFB smear and culture from
sputum as the standard screening method.4 6 7 11 13 17 To date,
there has been no direct comparison between the sensitivity of
samples from spontaneously expectorated sputum samples, and
sputum induced by use of hypertonic saline. Analysis of induced
sputum provides equal or better detection of ‘standard’ CF
pathogens76 and the procedure is in widespread use to collect
samples for mycobacterial culture among CF Centres worldwide.
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However, the Consensus Committee felt that, due to its incon-
venience, induced sputum collection should not be used as a
screening tool in individuals with no features suggestive of
NTM-PD who are incapable of spontaneously producing
sputum. As discussed in Microbiology section, there are currently
no other validated screening methods to detect NTM in indivi-
duals with CF. Although positive cultures have been detected
through laryngeal suction, oropharyngeal swabs, or gastric aspir-
ate, there are insufficient data to support their use. Skin testing
for delayed-type hypersensitivity against NTM antigens does not
appear sufficiently sensitive or specific to use for surveillance in
the CF population. Serological assays, such as IgG against
Mycobacterium antigen A60 for NTM surveillance, appear
promising,42 but have not been validated in the CF population.
MICROBIOLOGY
What respiratory tract samples should be used to evaluate
individuals with CF for suspected NTM-PD?
Recommendation 6: The CF Foundation and the ECFS recom-
mend that culture and smears for AFB from sputum, induced
sputum, bronchial washings or bronchoalveolar lavage samples
can be used to evaluate individuals with CF suspected to have
NTM-PD.
Recommendation 7: The CF Foundation and the ECFS rec-
ommend against the routine use of transbronchial biopsies to
detect NTM in individuals with CF suspected to have
NTM-PD.
Recommendation 8: The CF Foundation and the ECFS rec-
ommend against the use of oropharyngeal swabs to perform
diagnostic smears and cultures in individuals with CF suspected
to have NTM-PD.
Currently, sputum, induced sputum, bronchial washings and
bronchoalveolar lavage samples are routinely used to evaluate
individuals for suspected NTM-PD.77 Samples for NTM should
be processed for smear microscopy, preferably by fluorescence,
and for culture. Microscopy allows for direct evaluation of the
bacterial burden, and may indicate false-negative culture results
through excessive sample decontamination or overgrowth of
conventional bacteria. Oropharyngeal swabs should not be used
for the detection of NTM, since they do not consistently
provide sufficient material for culture.77
A staged approach should be adopted for obtaining diagnostic
samples; testing spontaneously expectorated or induced sputum
(if available) before resorting to bronchoscopy. Although there
are no published studies comparing the relative performance of
these different methods for detection of NTM, the presence of
negative sputum samples in individuals with radiological and
clinical suspicion of NTM disease should prompt CT-guided
bronchoscopic sampling, as, for example, in nodular bronchiec-
tatic disease.78–80 While trans-bronchial biopsies can reveal
NTM (on microscopy or culture) and may demonstrate granu-
lomatous inflammation (supporting NTM disease rather than
transient colonisation), they should not be obtained routinely in
individuals with CF given the significant risks of bleeding and
pneumothorax.81
How should respiratory tract samples from individuals with
CF be cultured for NTM?
Recommendation 9: The CF Foundation and the ECFS recom-
mend that respiratory tract samples should be cultured using
both solid and liquid media.
Recommendation 10: The CF Foundation and the ECFS rec-
ommend that the incubation duration for NTM cultures should
be for a minimum of 6 weeks.
Recommendation 11: The CF Foundation and the ECFS rec-
ommend that an NTM culture should be processed within 24 h
of collection to optimise the detection of NTM in respiratory
samples. If a delay in processing is anticipated, refrigeration of
samples is advised.
The most sensitive and rapid way to detect viable mycobac-
teria is to culture samples (following decontamination to
remove conventional bacteria and fungi) in liquid media using
an automated growth detection system (such as Mycobacteria
Growth Indicator Tube (MGIT)77 82 83); a process widely used
around the world. However, concomitant culture on solid
media may increase the diagnostic yield since NTM can be
detected despite incomplete sample decontamination.84 Since
decontamination procedures substantially reduce the viability of
mycobacteria in samples, attempts have been made to use
highly selective agar for solid culture of unprocessed sputum.
A recent study, using agar designed for Burkholderia cepacia
complex culture,84 demonstrated an improvement in detection
of rapidly growing mycobacteria from 0.7% with conventional
liquid culture to 2.8%. The duration, both of liquid and solid
culture methods, has not been rigorously tested but the vast
majority of pathogenic NTM will grow by 6 weeks—the
current recommended duration in US and European
laboratories.77
Laboratory processing of samples should ideally be performed
within 24 h of collection to avoid overgrowth by conventional
bacteria, which can reduce NTM viability85 and prevent success-
ful decontamination.85 Studies have shown that refrigeration of
samples may improve NTM detection from sputum samples86
and should be considered if delays longer than 24 h in process-
ing are anticipated.
How should respiratory tract samples from individuals with
CF be decontaminated to optimise the detection of NTM?
Recommendation 12: The CF Foundation and the ECFS recom-
mend that respiratory tract samples should be decontaminated
using the standard N-acetyl L-cysteine, NALC, (0.5%)-NaOH
(2%) method.
Recommendation 13: The CF Foundation and the ECFS rec-
ommend that, if a sample remains contaminated with
Gram-negative bacteria after standard NALC-NaOH decontam-
ination, it should be further treated with either 5% oxalic acid
or 1% chlorhexidine.
Adequate sample decontamination to remove conventional
bacteria and fungi is essential to permit culture-based detection
of mycobacteria,77 87 88 but often fails in CF samples given
high densities of P. aeruginosa and other microbes.39–41 89 90
Since enhanced decontamination protocols adversely impact on
NTM viability in samples,90 a two-step approach to sample
processing should be adopted.41 Virtually all US and European
clinical microbiology laboratories currently use an
NALC-NaOH decontamination step prior to mycobacterial
culture.41 87 88
The addition of a second decontamination step using oxalic
acid has been shown to permit the recovery of NTM from per-
sistently contaminated samples albeit with reduced sensitivity.40
Alternatively, use of 1% chlorhexidine as a first step may
improve the recovery of mycobacteria, but at the expense of
higher rates of residual sample contamination.89 Chlorhexidine
negatively affects the performance of the MGIT automated
liquid culture system, because it needs to be neutralised with
lecithin; lecithin generates random fluorescence reactions from
the MGIT system sensor, limiting its use.89
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Should non-culture-based methods be used to detect NTM
in respiratory tract samples from individuals with CF?
Recommendation 14: The CF Foundation and the ECFS recom-
mend against the use of non-culture-based methods for detect-
ing NTM in respiratory tract samples.
A number of studies have been published on the use of
PCR-based detection methods for NTM from respiratory
samples.91–95 To date, however, none have been robustly evalu-
ated for CF sputum samples, nor have they demonstrated suffi-
ciently high sensitivity and specificity on smear-negative
samples91 to recommend their routine diagnostic use.
Furthermore, the clinical significance of PCR-positive respira-
tory samples is currently unknown.
How should NTM isolates from individuals with CF be
identified?
Recommendation 15: The CF Foundation and the ECFS recom-
mend that all NTM isolates from individuals with CF should
undergo molecular identification.
Recommendation 16: The CF Foundation and the ECFS rec-
ommend that all NTM isolates from individuals with CF
should be identified to the species level, except for M. intracel-
lulare, M. avium and M. chimaera, where identification can be
limited to MAC and MABSC, which should be subspeciated.
As individual NTM species differ in their potential to cause
clinical disease in humans96 and in their response to specific
antibiotics, correct species identification of NTM isolates is clin-
ically important. Moreover, in the case of M. abscessus, the
ability to identify isolates to the subspecies level
(M. a. abscessus, M. a. bolletii, M. a. massiliense) may predict
treatment response97 and potentially permit targeted therapy.98
M. a. massiliense harbours a partial erm41 gene deletion, pre-
venting inducible macrolide resistance,97 99 and leads to more
successful outcomes with macrolide-based antibiotic regimens
than in infections with M. a. abscessus (which has a full length,
functional erm41 gene).97
There is no gold standard for NTM species identification.
Molecular methods have now surpassed biochemical tests for
NTM identification in many laboratories.100–107 Although
matrix-assisted laser desorption ionisation-time of flight mass
spectrometry has shown promise in providing rapid speciation
of NTM,108–112 the optimal method for protein extraction from
mycobacteria and the exact discriminatory power of this
method have yet to be established.
Among molecular methods, three techniques are in current
clinical use. The first includes line probe assays,103–105 113
which are easy to perform but costly, and permits accurate iden-
tification of the most frequently encountered NTM species but
not subspeciation of M. abscessus. The second technique is PCR
product restriction analysis in which amplified gene fragments
are restriction digested to yield different sized fragments, which
are then resolved by gel electrophoresis and correlated with spe-
cific species.114 This technique is mostly used in low-resource
settings and is at least comparable to the line probe assays.106
The third technique is (partial) gene sequencing, which permits
a higher level of discrimination, often to subspecies level, but is
only available in laboratories with access to sequencing facilities.
The choice of the optimal sequencing strategy is not straightfor-
ward. Although partial 16S ribosomal RNA (rRNA) gene
sequencing provides insufficient discrimination, particularly
between M. abscessus and M. chelonae,115 a number of
other gene sequences (such as partial hsp65 and rpoB gene
sequences) have been successfully used.107 116 For subspeciation
of M. abscessus, a multilocus sequence typing approach has
recently been validated.116–118 An alternative strategy close to
subspeciation is to measure erm gene associated inducible
macrolide resistance by phenotypic drug susceptibility testing
(DST). This does not distinguish accurately between M. absces-
sus subspecies but does offer the data for which the subspecia-
tion is generally performed—whether or not there is inducible
macrolide resistance.
Should DST be performed on NTM isolates from individuals
with CF?
Recommendation 17: The CF Foundation and the ECFS recom-
mend that for MAC, clarithromycin susceptibility testing should
be performed on an isolate recovered prior to initiation of treat-
ment. Clarithromycin susceptibility testing should also be per-
formed on subsequent isolates if the patient (a) fails to culture
convert after 6 months of NTM treatment; (b) recultures MAC
after initial culture conversion while on NTM treatment or (c)
recultures MAC after completion of NTM treatment.
Recommendation 18: The CF Foundation and the ECFS rec-
ommend that for MABSC, susceptibility testing should include
at least clarithromycin, cefoxitin and amikacin (and preferably
also tigecycline, imipenem, minocycline, moxifloxacin and
linezolid).
Recommendation 19: The CF Foundation and the ECFS rec-
ommend that DST should be performed in accordance with
CLSI guidelines.
Based on current published data, the exact role of DSTand its
potential to guide regimen selection and predict outcomes in
NTM lung disease in patients with CF, remains unknown.119
The CLSI has published guidelines on DST of NTM.17 120 121
Its European counterpart, the European Committee on
Antimicrobial Susceptibility Testing (EUCAST), presently has no
guidelines for DSTof NTM.77
It is important to appreciate that, although CLSI guidelines
provide breakpoint concentrations to interpret minimum inhibi-
tory concentrations (MICs) as ‘susceptible’ or ‘resistant’, these
cut-offs have had very limited clinical validation, and no clinical
validation has been performed in patients with CF. Moreover,
limited pharmacokinetic (PK) data are now available for MAC
lung disease to support breakpoint concentrations,122 there are
no representative PK or pharmacodynamic data to guide treat-
ment of patients with CF.
Breakpoints for clarithromycin susceptibility of MAC have
been validated in HIV-related disseminated MAC disease and in
retrospective series of MAC lung disease.119 123 124 Since the
presence of macrolide resistance predicts worse clinical out-
comes125 126 and requires augmented treatment,126 susceptibil-
ity to macrolides should be tested on isolates prior to treatment
initiation and during treatment in refractory cases defined as
those individuals who (1) fail to culture convert after 6 months
of NTM treatment; (2) reculture MAC after initial culture con-
version while on NTM treatment or (3) reculture MAC after
completion of NTM treatment.
A very recent study has shown that amikacin MICs >64 mg/L
are measured only in MAC isolates that have mutations asso-
ciated with amikacin resistance, that is, in the 16S rRNA gene.
These strains are cultured from patients with significant amino-
glycoside exposure, such as individuals with CF, and for disease
caused by these strains, amikacin is unlikely to have any benefi-
cial effect.127
For rapidly growing mycobacteria including M. abscessus,
clinical validation has only been performed in series of extra-
pulmonary disease,128 and only for cefoxitin, aminoglycosides
and co-trimoxazole. In series of M. abscessus lung disease, the
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outcomes of macrolide-based treatment are generally poor and
do not correlate well with in vitro susceptibilities119 129 poten-
tially due to erm41-dependent inducible macrolide resistance
and relative short duration of adequate regimens, which were
often interrupted because of toxicity. Indeed, in the absence of a
functional erm41 gene, response to macrolide-containing treat-
ments has been good.94 The CLSI has recommended routine
testing for inducible macrolide resistance by performing
extended incubation of isolates in the presence of clarithromy-
cin, as inducible resistance may predict treatment failure.120 For
M. simiae, the role of DST is unknown, although the generally
poor outcomes of treatment have been correlated with a lack of
synergistic activity between rifampicin and ethambutol, an in
vitro observation that still awaits clinical validation.130 Some
molecular methods to assess drug susceptibility exist, but are
not yet routinely available. For example, sequencing of the 16S
rRNA and 23S rRNA genes can reveal mutations associated
with high-level resistance to aminoglycosides and macrolides,
respectively.119 127
DIAGNOSIS OF NTM-PD IN CF
Should the ATS/IDSA criteria for the diagnosis of NTM-PD
be used in individuals with CF?
Recommendation 20: The CF Foundation and the ECFS recom-
mend that ATS/IDSA criteria for the diagnosis of NTM-PD
should be used in individuals with CF (ATS/IDSA 2007
Statement).
Recommendation 21: The CF Foundation and the ECFS rec-
ommend that other CF pathogens and comorbidities should be
considered as potential contributors to a patient’s symptoms
and radiological features when determining the clinical signifi-
cance of NTM-positive cultures.
Recommendation 22: The CF Foundation and the ECFS rec-
ommend that NTM treatment should be considered for indivi-
duals with CF who have ATS/IDSA defined NTM-PD.
Recommendation 23: The CF Foundation and the ECFS rec-
ommend that individuals receiving azithromycin as part of their
CF medical regimen who have a positive NTM culture should
not continue azithromycin treatment while evaluation for NTM
disease is underway, as azithromycin monotherapy may lead to
resistance. A macrolide agent may be included in a multidrug
treatment regimen if criteria are met for NTM disease.
In contrast to M. tuberculosis, a single positive culture of
NTM does not necessarily indicate that an individual has
NTM-PD. To address the difficulty of making a diagnosis of
NTM-PD, the ATS/IDSA proposed a set of clinical, radiological
and microbiological criteria required to define an individual as
having NTM-PD (ref 22; box 1). Although these criteria have
not been validated for individuals with CF, they have been
widely adopted by NTM specialists around the world and
provide an operational definition for NTM-PD, which supports
clinical decision-making and facilitates research. The Statements
Committee therefore concluded that, in the absence of an alter-
nate, CF-validated definition, the ATS/IDSA criteria should be
used for the definition of NTM-PD in individuals with CF.
Microbiological criteria for NTM-PD
Individuals should have two or more positive sputum cultures
of the same NTM species or one positive culture from broncho-
scopic lavage or wash. The threshold for the number of positive
sputum samples is derived from an observational study of
individuals without CF with MAC in which 98% individuals
with at least two positive sputum cultures developed progressive
radiographic change compared to only 2% with one positive
culture.131 The type of NTM species isolated is also important.
Thus, isolation of M. abscessus is more likely to reflect
NTM-PD than culturing usually non-pathogenic species such as
M. gordonae and M. terrae complex.
Radiological criteria for NTM-PD
In the context of CF-related lung disease, a chest radiograph is
unlikely to be of use for the investigation of NTM-PD.
High-resolution CT (HRCT) scan changes supporting a diagno-
sis of NTM-PD would include: inflammatory nodules, new
tree-in-bud opacities (particularly in areas of mild underlying
bronchiectasis) and cavitation.132 However, these changes are
non-specific, particularly in individuals with severe CF-related
lung disease, and may reflect infection with more common CF
pathogens, inadequate airway clearance or the development of
allergic bronchopulmonary aspergillosis (ABPA).
Clinical criteria for NTM-PD
NTM-PD should be suspected in individuals with worsening
respiratory symptoms (breathlessness, increased cough and
sputum production) and/or declining pulmonary function tests
that do not respond to antibiotic therapy targeting conventional
CF-associated bacteria and optimised airway clearance. Night
sweats, fevers, chest pains and weight loss (although uncom-
mon) may also suggest possible NTM-PD.
NTM treatment should be considered in individuals with CF
who fulfil ATS/IDSA criteria for NTM-PD. However, the deci-
sion to start treatment is a clinical one based on an
Box 1 ATS/IDSA clinical and microbiologic criteria for
diagnosing non-tuberculous mycobacterial pulmonary
disease (NTM-PD) (based on ref 22)
Clinical (both required)
1. Pulmonary symptoms with nodular or cavitary opacities on
chest radiograph, or a high-resolution CT scan that shows
multifocal bronchiectasis with multiple small nodules.
2. Appropriate exclusion of other diagnoses.
Microbiologic (one of the following required)
1. Positive culture results from at least two expectorated
sputum samples. If the results from samples are
non-diagnostic, consider repeat sputum acid-fast bacilli
(AFB) smears and cultures.
2. Positive culture results from at least one bronchial wash or
lavage.
3. Transbronchial or other lung biopsy with mycobacterial
histopathological features (granulomatous inflammation or
AFB) and positive culture for NTM or biopsy showing
mycobacterial histopathological features (granulomatous
inflammation or AFB) and one or more sputum or bronchial
washings that are culture positive for NTM.
A. Expert consultation should be obtained when either
infrequently encountered NTM or those usually
representing environmental contamination are recovered.
B. Patients who are suspected of having NTM-PD but who
do not meet the diagnostic criteria should be followed
until the diagnosis is firmly established or excluded.
C. Making the diagnosis of NTM-PD does not, per se,
necessitate the institution of therapy, which is a decision
based on potential risks and benefits of therapy for
individual patients.
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amalgamation of patient factors, the NTM species involved, the
risks of treatment side effects, adherence concerns and the
expected outcomes of treatment.
Recommended clinical practice for diagnosis
A suggested algorithm for the investigation of individuals with
CF suspected of having NTM-PD is shown in figure 1.
When being investigated for potential NTM-PD, individuals
should discontinue drugs liable to compromise NTM culture
(such as macrolides, fluoroquinolones, aminoglycosides,
co-trimoxazole, linezolid and doxycycline) prior to sputum
sample collection. In the case of azithromycin, intracellular
accumulation within phagocytes may require a washout period
of 2 weeks or more to allow for drug clearance.133 134 If
sputum samples are persistently culture negative, but clinical or
radiological suspicion of NTM-PD remains, bronchoscopy with
targeted sampling of areas with suggestive HRCT changes may
be indicated. Individuals receiving azithromycin as part of their
CF medical regimen, who have a positive surveillance NTM
culture, should not continue azithromycin treatment while
evaluation for NTM disease is underway, as azithromycin mono-
therapy may lead to the development of macrolide resistance.
Other CF pathogens and comorbidities should be considered
as potential contributors to a patient’s symptoms and radio-
logical features when determining the clinical significance of
NTM-positive cultures. All aspects of CF care should be
reviewed and optimised in order to determine the clinical sig-
nificance of NTM in the sputum. Specifically, consider a trial of
NTM-sparing intravenous antibiotics (ie, avoid carbapenems,
cefoxitin, tigecycline, fluoroquinolones, linezolid and amikacin)
that target conventional bacteria; and assess for CF-related dia-
betes, uncontrolled gastrointestinal reflux disease, and clinical
and immunological features of ABPA. Likewise, adequate
treatment of sinus disease, nutritional support and effective
airway clearance strategies should be implemented.
Before starting NTM treatment, side effects, the importance
of adherence to therapy and complications of treatment should
be discussed with patients, and these discussions documented in
the medical notes. Discussion of the risk of treatment failure
should be clearly documented.
TREATMENT
Which antibiotic regimen should be used in individuals with
CF who have ATS/IDSA-defined MABSC pulmonary disease?
Recommendation 24: The CF Foundation and the ECFS recom-
mend that treatment of MABSC pulmonary disease should
involve an intensive phase followed by a continuation phase.
Recommendation 25: The CF Foundation and the ECFS rec-
ommend that the intensive phase should include a daily oral
macrolide (preferably azithromycin) in conjunction with 3–
12 weeks of intravenous amikacin and one or more of the fol-
lowing: intravenous tigecycline, imipenem or cefoxitin, guided
but not dictated by DST. The duration of intensive phase
therapy should be determined by the severity of infection, the
response to treatment and the tolerability of the regimen.
Recommendation 26: The CF Foundation and the ECFS rec-
ommend that the continuation phase should include a daily oral
macrolide (preferably azithromycin) and inhaled amikacin, in
conjunction with 2–3 of the following additional oral antibio-
tics: minocycline, clofazimine, moxifloxacin and linezolid,
guided but not dictated by DST.
Recommendation 27: The CF Foundation and the ECFS rec-
ommend that individuals with MABSC pulmonary disease
should be managed in collaboration with experts in the treat-
ment of NTM and CF, as drug intolerance and drug-related
Figure 1 A suggested algorithm for the investigation of individuals with clinical suspicion of NTM-PD (AFB, acid-fast bacilli; CF, cystic fibrosis;
FEV1, forced expiratory volume in 1 s; HRCT, high-resolution CT; NTM-PD, non-tuberculous mycobacteria pulmonary disease).
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toxicity occur frequently, and changes in antibiotic therapy are
often required.
Recommendation 28: The CF Foundation and the ECFS rec-
ommend that monotherapy with a macrolide or other anti-
microbial should never be used in the treatment of MABSC
pulmonary disease.
There are no published randomised controlled trials evaluat-
ing treatment outcomes in individuals with M. abscessus pul-
monary infections. Current treatment recommendations from
the ATS and IDSA recommend consideration of a multidrug
treatment regimen, but note that long-term sputum conversion
is difficult to achieve and thus, alternative goals such as symp-
tomatic improvement, radiographic regression of opacities or
microbiological improvement, may be more realistic.26 The
ATS/IDSA recommendations were based primarily on a single
large study of 154 patients with lung disease caused by rapidly
growing mycobacteria, in which more than 80% of patients
were infected by M. abscessus.135 Treatment outcomes were
extremely poor; however, the patients did not receive the cur-
rently recommended combination of antibiotics.
Since the publication of the last ATS/IDSA guidelines,26 there
have been several studies that reported treatment outcomes in
individuals without CF with pulmonary disease due to M.
abscessus. Jeon et al136 described treatment outcomes in 65
non-CF adults, in South Korea, with M. abscessus lung disease,
who received a standardised treatment regimen. The regimen
included 4 weeks of amikacin (15 mg/kg/day in two divided
doses) and cefoxitin (200 mg/kg/day in three divided doses)
along with clarithromycin (1000 mg/day in two divided doses),
ciprofloxacin (1000 mg/day in two divided doses) and doxycyc-
line (200 mg/day in two divided doses). The total duration of
therapy was 24 months and at least 12 months after sputum
culture conversion. Fifty-four (83%) patients responded with
improved symptoms and 48 (74%) with improved HRCT find-
ings. Sputum conversion and maintenance of negative sputum
cultures for more than 12 months was achieved in 38 (58%)
patients. This rate was significantly lower (17%) in patients
whose isolates were resistant to clarithromycin. In contrast, in
the 14 (22%) patients who underwent resectional surgery, nega-
tive sputum cultures were achieved and maintained in 7 (88%)
of 8 with preoperatively positive cultures. The authors con-
cluded that a standardised regimen was moderately effective,
but adverse reactions were frequent.
Among 107 patients with M. abscessus pulmonary infection
at National Jewish Health in Denver, CO, 69 non-CF indivi-
duals were treated and followed for a mean duration of 34
months.129 Patients were treated with individualised treatment
regimens following ATS/IDSA recommendations. Twenty (29%)
patients remained culture positive, 16 (23%) converted but
experienced relapse, 33 (48%) converted to negative and did
not relapse, while 17 (16%) died during the study period.
There were significantly more surgical patients than medical
patients whose culture converted and remained negative for at
least 1 year (57% vs 28%, p=0.022). As in the previous study
from South Korea, surgery may have been beneficial. However,
surgical management is less likely to be applicable in individuals
with CF in whom focal pulmonary disease is uncommon.
In a follow-up study, Koh et al97 reported significant differ-
ences in outcomes based on which subspecies of M. abscessus
was causing the infection. Treatment response rates to a standar-
dised multidrug regimen were much higher in patients with
M. a. massiliense than in those with M. a. abscessus: sputum
culture conversion occurred in 88% of patients with
M. a. massiliense compared with 25% with M. a. abscessus
(p<0.001). All of the M. a. abscessus isolates contained a full
length, functional erm41 that was shown to result in inducible
macrolide resistance when the isolates were incubated with clari-
thromycin. In contrast, the MIC of M. a. massiliense strains did
not increase after incubation with the macrolide agent because
the erm41 gene contained a deletion, making it non-functional.
Recent data from this same group of investigators have indicated
that clarithromycin is a much stronger inducer of erm41 than
azithromycin, suggesting that the latter macrolide may be a
better choice when treating M. a. abscessus infections.98
Despite the clinical significance of M. abscessus lung infection
in patients with CF, data on treatment outcomes are extremely
limited. There is one anecdotal report that describes eradication
of M. abscessus in an individual with CF who received a pro-
longed course of therapy with alternating month inhaled amika-
cin plus oral clarithromycin.137 However, this appears to be an
uncommon outcome in practice. A recent case series of 52 indi-
viduals, including 15 with CF, with M. abscessus and/or M. che-
lonae infection, suggests that tigecycline-based regimens may be
of benefit, with 10/15 individuals with CF showing some
improvement.138
Recommended clinical practice for antibiotic treatment for
M. abscessus pulmonary disease in CF
A typical treatment schedule for individuals with CF with
M. abscessus infection is shown in figure 2. Antibiotic dosing
regimens are listed in table 2 with important side effects/toxici-
ties described in table 3.
Given the lack of clinical trial data to inform treatment deci-
sions there is a lot of variation in how patients are treated. An
initial intensive phase is typically used to rapidly decrease the
bacterial load. A combination of two intravenous drugs with
demonstrated in vitro activity is administered for several weeks
to months in combination with one or more oral drugs.
Intravenous drug regimens of amikacin with cefoxitin and/or
imipenem and/or tigecycline are the most commonly used com-
binations. Oral drugs with demonstrated in vitro activity include
the macrolides (clarithromycin and azithromycin), linezolid, clo-
fazimine and, occasionally, ciprofloxacin and/or moxifloxacin.
After the intensive phase of therapy, patients are usually treated
with at least two oral drugs in addition to a macrolide with or
without inhaled antibiotics.
However, there is growing concern that treatment of
M. abscessus isolates that have either a functional erm41 gene
(resulting phenotypically in inducible macrolide resistance) or a
23S rRNA mutation (leading to high level constitutive macrolide
resistance) may be compromised by switching from intravenous
to oral therapy (given the relatively poor efficacy of oral antibio-
tics) and, therefore, continuous/very extended intravenous
therapy with two or more effective antibiotics may be indicated
in these cases.
The choice of intravenous agents is based on in vitro activity
and the toxicity profile of the drug. In addition to amikacin, imi-
penem is perhaps the best choice as companion intravenous
therapy; the drug shows in vitro activity and the side effect
profile is better than that of cefoxitin and tigecycline. In the study
reported by Jeon et al,136 60% of the patients started on cefoxitin
had to have the drug discontinued due to drug-related toxicity,
after a median of 22 days of treatment. Neutropaenia occurred in
51% and thrombocytopaenia in 6% of patients on cefoxitin.
Tigecycline has a low MIC against M. abscessus and showed effi-
cacy against M. abscessus in combination.138 However, it is asso-
ciated with significant nausea and vomiting, which has made it
difficult to administer for a prolonged period.138
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There are few oral drugs with significant in vitro activity
against M. abscessus; the macrolides are the only oral drugs
with consistent activity although their use may be potentially
limited by inducible resistance (as described above) or acquired
point mutations in the 23S rRNA. There are no clinical trials
comparing azithromycin to clarithromycin in M. abscessus infec-
tion, so the choice of which macrolide to use is typically based
on the in vitro activity, side effects profile and consideration of
drug interactions. Clarithromycin has slightly better in vitro
activity than azithromycin but there are conflicting reports
regarding the impact of erm41 gene expression with each of
these drugs.98 139 140 Clarithromycin is a stronger inhibitor of
the P450 enzyme system than is azithromycin, so drug interac-
tions are more common.
Linezolid shows in vitro activity in approximately 50% of
M. abscessus isolates (although there is considerable geograph-
ical variation); however, haematological (anaemia, thrombocyto-
paenia) and neurological (peripheral neuropathy, optic neuritis)
toxicities are common, particularly when linezolid is dosed
600 mg two times a day for prolonged courses. For this reason,
many practitioners give 600 mg once daily to reduce the risk of
adverse effects. However, care should be exercised in individuals
chronically co-infected with methicillin-resistant Staphylococcus
aureus (MRSA) since long-term linezolid therapy may encourage
MRSA resistance. The fluoroquinolones and minocycline/doxy-
cycline rarely show in vitro activity although they were included
in the standardised treatment regimen used in the report by
Jeon et al.98 Finally, clofazimine has significant in vitro activity
against M. abscessus.141 However, this drug, used to treat
leprosy, is not readily available in the USA at this time, although
it can be obtained with an IRB-approved protocol through sub-
mission of an individual patient use IND to the Food and Drug
Administration. Instructions for this process can be found on
the NTM Info and Research, Inc, website (http://www.ntminfo.
org/clofazimine).
The lack of oral antibiotics with activity against M. abscessus
has led clinicians to use inhaled amikacin, usually during the
continuation phase of therapy. There are no studies correlating
treatment outcomes in patients with M. abscessus infection with
the dose of inhaled amikacin and, therefore, there is a great deal
of variation in the dose used (250–500 mg), and frequency of
administration (daily to twice daily). A recent study, targeting
treatment refractory NTM patients, most of whom were
without CF with M. abscessus, evaluated the effect of adding
inhaled amikacin to their oral and/or intravenous drug regi-
mens.142 Among the 20 patients with persistently positive cul-
tures, 8 (40%) had at least one negative culture and 5 (25%)
had persistently negative cultures after addition of inhaled ami-
kacin. Inhaled amikacin was stopped in 7 (35%) due to toxicity.
There is currently significant interest in the potential use of a
liposomal formulation of amikacin (which may improve drug
delivery within the lung and into infected macrophages) as part
of a multidrug regimen for both M. abscessus and MAC. Large
multicentre studies are ongoing.
The optimum duration of therapy is not known. Based on
studies in individuals without CF, even prolonged treatment
regimens were associated with high rates of failure and recur-
rence. Many patients who do not convert their cultures to nega-
tive on therapy may still benefit from continuing or repeating
courses of treatment.
Figure 2 Typical treatment schedules for individuals with CF with Mycobacterium abscessus or MAC pulmonary disease. (A) M. abscessus
treatment is divided into an initial intensive phase with an oral macrolide (preferably azithromycin) and intravenous amikacin with one or more
additional intravenous antibiotics (tigecycline, imipenem, cefoxitin) for 3–12 weeks (depending on severity of infection, response to treatment, and
the tolerability of the regimen), followed by a continuation phase of oral macrolide (preferably azithromycin) and inhaled amikacin with 2–3
additional antibiotics (minocycline, clofazimine, moxifloxacin, linezolid). Antibiotic choices should be guided but not dictated by drug susceptibility
testing. Baseline and interval testing for drug toxicity is essential (B). MAC treatment (for clarithromycin-sensitive disease) should be with a daily
oral macrolide (preferably azithromycin), rifampin and ethambutol. An initial course of injectable amikacin or streptomycin should be considered in
the presence of (i) AFB smear positive respiratory tract samples, (ii) radiological evidence of lung cavitation or severe infection and (iii) systemic
signs of illness. Baseline and interval testing for drug toxicity is essential (AFB, acid-fast bacilli; CF, cystic fibrosis; HRCT, high-resolution CT; MAC,
Mycobacterium avium complex).
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Treatment for MAC
Which antibiotic regimen should be used in individuals with CF
who have ATS/IDSA-defined MAC pulmonary disease?
Recommendation 29: The CF Foundation and the ECFS recom-
mend the same antibiotic regimen for treatment of all species
within the MAC.
Recommendation 30: The CF Foundation and the ECFS rec-
ommend that clarithromycin-sensitive MAC pulmonary disease
should be treated with a daily oral antibiotic regimen containing
a macrolide (preferably azithromycin), rifampin and
ethambutol.
Recommendation 31: The CF Foundation and the ECFS
recommend against the use of intermittent (three times per
week) oral antibiotic therapy to treat MAC pulmonary
disease.
Recommendation 32: The CF Foundation and the ECFS rec-
ommend that monotherapy with a macrolide or other anti-
microbial agent should never be used in the treatment of MAC
pulmonary disease.
Recommendation 33: The CF Foundation and the ECFS
recommend that an initial course of intravenous amikacin
should be considered for the treatment of MAC pulmonary
disease in the presence of one or more of the following: (i) AFB
smear positive respiratory tract samples, (ii) radiological evi-
dence of lung cavitation or severe infection and (iii) systemic
signs of illness.
Recommendation 34: The CF Foundation and the ECFS rec-
ommend that clarithromycin-resistant MAC pulmonary disease
should be managed in collaboration with experts in the treat-
ment of NTM and CF.
Table 2 Antibiotic-dosing regimens used to treat Mycobacterium avium complex and Mycobacterium abscessus complex pulmonary disease in
cystic fibrosis
Antibiotic Route Dose suitable for children/adolescents Dose suitable for adults
Amikacin* Intravenous Children: 15–30 mg/kg/dose once daily
Adolescents: 10–15 mg/kg/dose once daily
Maximum dose 1500 mg daily
10–30 mg/kg once daily
or
15 mg/kg/day in two divided doses
Daily to 3× weekly dosing
Amikacin*†‡ Nebulised 250–500 mg/dose once or twice daily 250–500 mg once or twice daily
Azithromycin Oral Children: 10–12 mg/kg/dose once daily
Adolescents: adult dosing regimen
Maximum dose 500 mg
250–500 mg once daily
Cefoxitin Intravenous 50 mg/kg/dose thrice daily (maximum dose 12 g/day) 200 mg/kg/day in three divided doses (maximum
dose 12 g/day)
Clarithromycin Oral 7.5 mg/kg/dose twice daily (maximum dose 500 mg) 500 mg twice daily§
Clarithromycin Intravenous Not recommended 500 mg twice daily§
Clofazimine†¶ Oral 1–2 mg/kg/dose once daily (maximum dose 100 mg) 50–100 mg once a day
Co-trimoxazole (sulfamethoxazole
and trimethoprim)
Oral 10–20 mg/kg/dose twice daily 960 mg twice daily
Co-trimoxazole (sulfamethoxazole
and Trimethoprim)
Intravenous 10–20 mg/kg/dose twice daily 1.44 g twice daily
Ethambutol Oral Infants and children: 15 mg/kg/dose once daily
Adolescents: 15 mg/kg/dose once daily
15 mg/kg once daily
Imipenem Intravenous 15–20 mg/kg/dose twice daily (maximum dose 1000 mg) 1 g twice daily
Linezolid** Oral <12 years old: 10 mg/kg/dose thrice daily
12 years and older: 10 mg/kg/dose once or twice daily
(maximum dose 600 mg)
600 mg once or twice daily
Linezolid** Intravenous <12 years old: 10 mg/kg/dose thrice daily
12 years and older: 10 mg/kg/dose once or twice daily
(maximum dose 600 mg)
600 mg once or twice daily
Moxifloxacin Oral 7.5–10 mg/kg/dose once daily (maximum dose 400 mg daily) 400 mg once daily
Minocycline Oral 2 mg/kg/dose once daily (maximum dose 200 mg) 100 mg twice daily
Rifampin (Rifampicin) Oral 10–20 mg/kg/dose once daily (maximum dose 600 mg) <50 kg 450 mg once daily
>50 kg 600 mg once daily
Rifabutin Oral 5–10 mg/kg/dose once daily (maximum dose 300 mg) 150–300 mg once daily
150 mg if patient taking strong CYP3A4 inhibitor
450–600 mg if patient taking strong CYP3A4 inducer
Streptomycin* Intramuscular/
intravenous
20–40 mg/kg/dose once daily (maximum dose 1000 mg) 15 mg/kg once daily (maximum dose 1000 mg)
Tigecycline†,†† Intravenous 8–11 years: 1.2 mg/kg/dose twice daily (maximum dose
50 mg)
12 years and older: 100 mg loading dose and then 50 mg
once or twice daily
100 mg loading dose and then 50 mg once or twice
daily
*Adjust dose according to levels. Usually, starting dose is 15 mg/kg aiming for a peak level of 20–30 mg/mL and trough levels of <5–10 micrograms/ml.
†As tolerated.
‡Mixed with normal saline.
§For individuals under 55 kg, many practitioners recommend 7.5 mg/kg twice daily.
¶Only available in the USA through an IND application to the FDA.
**Usually given with high dose (100 mg daily) pyridoxine (vitamin B6) to reduce risk of cytopaenias.
††Many practitioners recommend pre-dosing with one or more anti-emetics before dosing and/or gradual dose escalation from 25 mg daily to minimise nausea and vomiting.
IND, investigational new drug; FDA, Food and Drug Administration.
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There are very few published randomised controlled trials
evaluating treatment for MAC pulmonary disease (MAC-PD) in
non-HIV-positive patients and none in individuals with CF. In
the pre-macrolide era, a UK trial of individuals without CF and
with largely cavitary disease reported that those randomised to
receive rifampin and ethambutol had a combined failure/relapse
rate of 41% compared to 16% of patients randomised to
receive rifampin, ethambutol and isoniazid (p=0.033).143 In a
subsequent study on a similar cohort, patients randomised to
receive rifampin, ethambutol and clarithromycin had an all-
cause mortality of 48% compared to 30% of patients rando-
mised to receive rifampin, ethambutol and ciprofloxacin.144
Table 3 Important side effects/toxicities of antibiotics and advisable monitoring procedures for MAC and MABSC in CF
Drug Common side effects/toxicity Monitoring procedures
Amikacin Nephrotoxicity Regular serum amikacin levels*
Regular serum creatinine levels
Auditory-vestibular toxicity (tinnitus, high-frequency hearing loss) Symptoms, baseline and interval audiograms
Azithromycin Nausea, vomiting, diarrhoea Symptoms
Auditory-vestibular toxicity Symptoms, audiogram
Prolonged QT ECG
Clarithromycin Hepatitis Liver function tests
Taste disturbance Symptoms
Inhibited hepatic metabolism of rifabutin Symptoms
Cefoxitin Fever, rash Symptoms
Eosinophilia, anaemia, leucopaenia, thrombocytopaenia Full blood count
Interference with common assays to measure serum creatinine Use alternative assay
Clofazimine Discoloration of skin† Symptoms
Enteropathy (sometimes mimicking pancreatic insufficiency)† Symptoms
Nausea and vomiting Symptoms
Co-trimoxazole Nausea, vomiting, diarrhoea Symptoms
Anaemia, leucopoenia, thrombocytopaenia Full blood count
Fever, rash, Stevens-Johnson syndrome Symptoms
Ethambutol Optic neuritis Symptoms (loss of colour vision/acuity)
Baseline and interval testing for colour vision and acuity‡
Ophthalmology opinion if symptoms occur
Peripheral neuropathy Symptoms; nerve conduction studies
Imipenem Hepatitis Liver function tests
Imipenem (cont) Nausea, vomiting, diarrhoea Symptoms
Linezolid Anaemia, leucopaenia, thrombocytopaenia Full blood count
Peripheral neuropathy Symptoms/clinical evaluation/electrophysiology
Optic neuritis Symptoms (loss of colour vision/acuity)
Baseline and interval testing for colour vision and acuity
Ophthalmology opinion if symptoms occur
Moxifloxacin Nausea, vomiting, diarrhoea Symptoms
Insomnia, agitation, anxiety Symptoms
Tendonitis Symptoms
Photosensitivity Symptoms
Prolonged QT ECG
Minocycline Photosensitivity Symptoms
Nausea, vomiting, diarrhoea Symptoms
Vertigo Symptoms
Skin discolouration Clinical evaluation
Rifampin and rifabutin Orange discolouration of bodily fluids (can stain contact lenses) Symptoms
Hepatitis Liver function tests
Nausea, vomiting, diarrhoea Symptoms
Fever, chills Symptoms
Thrombocytopaenia Full blood count
Renal failure (rifampin) Blood tests
Increased hepatic metabolism of numerous drugs Dose adjustment of other medications/serum levels where available
Rifabutin Leucopaenia, Full blood count
Anterior uveitis (when combined with clarithromycin) Symptoms
Flu-like symptoms polyarthralgia, polymyalgia Symptoms
Streptomycin Nephrotoxicity Regular serum streptomycin levels
Regular serum creatinine levels
Auditory-vestibular toxicity (tinnitus, high frequency hearing loss) Symptoms, baseline and interval audiograms
Tigecycline Nausea, vomiting, diarrhoea Symptoms
Pancreatitis Serum amylase§
Hypoproteinaemia Serum albumin
Bilirubinaemia Serum bilirubin
*Usually aiming for peak levels of 20–30 mg/mL and trough levels of <5–10 mg/mL.
†It may take up to 3 months for toxicity to resolve following cessation of clofazimine due to its long half-life.
‡Monthly checks if receiving 25 mg/kg/day.
§In individuals with pancreatic sufficiency.
CF, cystic fibrosis; MABSC, Mycobacterium abscessus complex; MAC, Mycobacterium avium complex.
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However, only 13% of patients in the clarithromycin group
failed treatment or relapsed compared to 23% in the ciprofloxa-
cin group.
In addition, there have been several non-comparator studies
evaluating outcomes in HIV-negative patients with MAC-PD.
The majority utilised a three oral drug regimen including a
macrolide (clarithromycin or azithromycin), a rifamycin (rifam-
pin or rifabutin) and ethambutol, in combination with an initial
course of an aminoglycoside (streptomycin, amikacin or kana-
mycin).124 125 145–148 The culture conversion rate varied consid-
erably between studies (13–82%), but on the whole, in 55–65%
of patients, the culture converted after 6–12 months treatment
and, when reported, the mean time from starting treatment to
culture conversion was 3–5 months.124 125 Treatment failure
was associated with previous MAC-PD treatment, cavitary
disease, smear positivity, clarithromycin resistance at initiation
of treatment, intolerance of NTM therapy and acquired clari-
thromycin resistance.124 125 145 147–149
An alternative regimen using clofazimine with a macrolide
and ethambutol in a study of 30 patients resulted in a culture
conversion rate of 87% and a treatment success rate of 67%.150
Although 5 (19%) patients relapsed an average of 17 months
after completing treatment, all MAC isolates remained clarithro-
mycin sensitive, raising the possibility of reinfection rather than
treatment failure.151 In another case series utilising clofazimine
in combination with clarithromycin and minocycline, the
culture conversion rate was 64% in patients completing the
study (47% overall), which may indicate the importance of eth-
ambutol as part of the multidrug regimen in the treatment of
MAC-PD.152
Clarithromycin resistance developed in up to 15% of patients
receiving treatment for MAC-PD and this was generally asso-
ciated with clarithromycin monotherapy or the prescription of
inadequate companion medications.124–126 146–149 When taken
in combination with ethambutol and a rifamycin, acquired clari-
thromycin resistance developed in only 12/303 (4%) of patients.
In the context of clarithromycin resistance, the best treatment
responses were seen in patients who underwent surgical resec-
tion and received >6 months of an injectable aminoglycoside
(amikacin or streptomycin),124–126 as 11/14 (79%) so treated
achieved culture conversion compared to 1/27 (4%) of those
not surgically resected and not receiving injectables.123
While intermittent and daily dosing regimens appear equally
effective in several case series of individuals without CF, inter-
mittent regimens may be associated with less toxicity, better tol-
erability and adherence, and lower cost.147 148 However, a large
multicentre study utilising an intermittent dosing regimen in
individuals with moderate or severe MAC-PD (including many
with cavitary disease and with prior treatment failure), reported
a culture conversion rate of only 13% after 12 months of treat-
ment.146 151 There have, to date, been no studies in individuals
with CF to determine an optimal dosing regimen for MAC
therapy, but concerns about drug absorption and lung penetra-
tion in CF have meant that many centres have adopted daily
dosing protocols.
It is unclear if use of an aminoglycoside during the initial
phase of MAC antibiotic therapy is beneficial. In a multicentre
study involving 146 HIV-negative patients with MAC-PD, parti-
cipants were randomised to receive intramuscular streptomycin
(15 mg/kg) or placebo thrice weekly for the first 3 months of
therapy, in addition to clarithromycin, rifampin and ethambutol.
Streptomycin-treated patients had a significantly higher culture
conversion rate after approximately 2 years of treatment than
did placebo patients (71% vs 51%, p<0.05), but a third of
patients in each group experienced sputum relapse and there
were no significant differences in symptoms or radiological
response between groups.153 Furthermore, there was no statistic-
ally significant difference in culture conversion rates between
individuals who received an initial course of intramuscular kana-
mycin (78%) compared to those who did not (58%) in a non-
randomised study involving patients with MAC-PD.125 Recently,
the use of aerosolised amikacin in addition to standard multi-
drug macrolide-based regimens was reported in six
HIV-negative individuals with MAC-PD who had failed stand-
ard therapy.154 While four patients were culture negative after
6 months of therapy, one later cultured M. chelonae (resistant to
amikacin), two re-cultured MAC and one patient was unable to
tolerate prolonged therapy with aerosolised amikacin. A recent
case series of the impact of nebulised amikacin (250 mg once or
twice daily)142 in 20 individuals without CF with treatment
refractory NTM-PD (of whom 5 had MAC) reported adverse
events in 35% of cases. Two patients discontinued therapy due
to hearing loss. Studies examining the use of liposomal amikacin
(which may have a better side effects profile) for the treatment
of NTM in individuals with CF are ongoing.
Recommended clinical practice antibiotic treatment for MAC-PD
in CF
A typical treatment schedule for individuals with CF with MAC
infection is shown in figure 2. Antibiotic dosing regimens are
listed in table 2 with important side effects/toxicities described
in table 3.
Individuals with clarithromycin sensitive MAC-PD should be
treated with a daily oral antibiotic regimen that includes a
macrolide, rifampin and ethambutol (15 mg/kg), consistent with
the ATS/IDSA recommendations for individuals with severe
nodular bronchiectatic disease.26 Intermittent oral antibiotic
therapy is not recommended due to the nature of the underlying
lung disease and concerns regarding antibiotic absorption in CF.
While there are no head to head trials showing a difference in
outcome between individuals with MAC-PD treated with clari-
thromycin or azithromycin, the latter may be the macrolide of
choice in CF, as it can be taken once daily, its serum levels may
be less affected by rifamycins122 and it has well established ben-
efits in individuals with CF in addition to its effects on NTM.
Individuals with a high bacterial load (suggested by smear
positivity, radiological evidence of lung cavitation and/or signifi-
cant inflammatory change or the presence of systemic symp-
toms) may benefit from an initial (1–3 month) course of
injectable amikacin or streptomycin, in addition to the standard
three-drug regimen for MAC-PD. While the available data do
not show a difference in toxicity between amikacin regimens
dosed at 15 mg/kg once daily or 25 mg/kg thrice weekly, ototox-
icity was found in 37% of all participants (associated with older
age and larger cumulative dose), vestibular toxicity in 8%
(usually reversible) and nephrotoxicity in 15% (usually mild and
reversible).155 Streptomycin, although less widely used for
MAC-PD than amikacin, may have less ototoxicity than amika-
cin.155 The use of aerosolised amikacin in place of an intraven-
ous aminoglycoside may be preferable in terms of reduced
burden of care and toxicity, but outcome data are limited and it
is unlikely to be helpful for patients with cavitary disease in
whom drug levels at the site of infection may be subtherapeutic.
The major risk factors for the development of clarithromycin-
resistant MAC-PD are macrolide monotherapy and prior macro-
lide treatment with inadequate companion medications. Thus,
macrolides (often prescribed for their anti-inflammatory effects
in CF) should be discontinued immediately following isolation
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of a mycobacterial species, and macrolides should never be pre-
scribed in the treatment of MAC-PD without two appropriate
companion antibiotics.
Macrolide therapy is not generally recommended in the
context of clarithromycin-resistant MAC-PD,26 but macrolides
may still be beneficial in this context in CF due to their non-
antibiotic properties. Individuals with clarithromycin-resistant
MAC-PD may respond to a regimen including a parenteral ami-
noglycoside, a rifamycin (usually rifabutin) and ethambutol, in
addition to one or more companion medications (accepting that
there are limited data to guide practice)26 126 144 such as a quin-
olone or clofazimine. Rifabutin may be useful in the treatment
of clarithromycin-resistant MAC-PD, but adverse events (par-
ticularly blood dyscrasias, gastrointestinal upset and polyarthral-
gia) are more common and often necessitate dose reduction or
complete cessation of treatment.156–158 Surgical resection might
also be helpful in selected individuals with localised severe
bronchiectatic disease, but this management is less likely to be
useful in CF as MAC-PD is more likely to be diffuse.
Ethambutol ocular toxicity (optic or retrobulbar neuritis) may
present with blurred vision, decreased acuity, central scotomas,
impaired red-green colour discrimination and peripheral visual
field defects. Ocular toxicity was identified in 6% of individuals
without CF with MAC-PD receiving ethambutol at a dose of
25 mg/kg/day for the first 2 months followed by 15 mg/kg/day
for the remainder of treatment.159 Ocular toxicity is more likely
to occur in the context of MAC-PD than in patients receiving
tuberculosis (TB) treatment due to the longer duration of
therapy. While individuals prescribed ethambutol should have
regular visual acuity and colour vision testing, visual symptoms
often occur before measurable changes can be identified. Thus,
patients should be educated about the potential side effects of
ethambutol and encouraged to self-report changes in vision, fol-
lowing which ethambutol therapy should be discontinued until
an ophthalmological assessment has taken place.
It is not uncommon for more than one NTM species to be
isolated from an individual with CF.6 30 In these circumstances,
continued microbiological surveillance is advisable to determine
which species is/are persistently positive and which is/are likely
to be causing disease. NTM-PD is also commonly associated
with ABPA and/or the identification of Aspergillus spp in
sputum or lavage specimens. As rifamycins increase the hepatic
metabolism of azole antifungal agents, the treatment of
Aspergillus in the context of MAC-PD is more difficult. One
approach is to use rifabutin in place of rifampin (as it is the rifa-
mycin with the least cytochrome P450 enzyme induction) in
conjunction with the usual companion medications for MAC
and voriconazole, or posaconazole, which may be less affected
by rifabutin co-medication than voriconazole is, with adjustment
of drug doses according to levels.160 161 If therapeutic drug
monitoring (TDM) is not available, other approaches include
using nebulised amikacin or clofazimine in place of rifampin.150
Treatment: generic recommendations
What outcome monitoring should be performed in individuals
with CF receiving treatment for NTM-PD?
Recommendation 35: The CF Foundation and the ECFS recom-
mend that individuals with CF receiving NTM treatment should
have expectorated or induced sputum samples sent for NTM
culture every 4–8 weeks throughout the entire course of treat-
ment to assess the microbiological response.
Recommendation 36: The CF Foundation and the ECFS rec-
ommend that a schedule for detecting drug toxicity (including
hearing loss, visual loss, renal impairment and liver function
test abnormalities) should be set in place at the time of NTM
treatment initiation and implemented throughout treatment
based on the specific drugs prescribed.
Recommendation 37: The CF Foundation and the ECFS rec-
ommend that an HRCT scan of the lungs should be performed
shortly before starting NTM treatment and at the end of NTM
treatment, to assess the radiological response.
What duration of antibiotic therapy is recommended for
individuals with CF receiving treatment for NTM-PD?
Recommendation 38: The CF Foundation and the ECFS recom-
mend that NTM antibiotic therapy should be prescribed for
12 months beyond culture conversion (defined as three consecu-
tive negative cultures, with the time of conversion being the
date of the first of the three negative cultures) as long as no
positive cultures are obtained during those 12 months.
Recommendation 39: The CF Foundation and the ECFS rec-
ommend that individuals who fail to culture convert despite
optimal NTM therapy may benefit from long-term suppressive
antibiotic treatment.
Treatment: TDM
Should TDM be performed in individuals with CF receiving
treatment for NTM-PD?
Recommendation 40: The CF Foundation and the ECFS recom-
mend that, when amikacin is given intravenously or when
streptomycin is given intravenously or intramuscularly, serum
levels should be monitored and dosing adjusted to minimise
ototoxicity and nephrotoxicity.
Recommendation 41: The CF Foundation and the ECFS rec-
ommend against routinely obtaining serum levels of other anti-
mycobacterial drugs. However, absorption of oral medications
is often reduced in CF. Therefore use of TDM should be consid-
ered for individuals failing to improve despite taking recom-
mended drug regimens or for those on concomitant medications
with significant interactions with NTM drugs.
TDM seeks to quantify the relationship between drug dose,
serum (plasma) concentration and clinical response,162 and to
thereby maximise therapeutic response while avoiding toxicity.
The potential benefits of TDM during NTM treatment in indi-
viduals with CF include adjusting drug dosing to:
A. Correct for drug–drug interactions that could adversely affect
serum antibiotic levels: Drug–drug interactions frequently
occur among agents used to treat NTM. Rifampin (more
than rifabutin) may increase the metabolism of several drugs
including clarithromycin, azithromycin and moxifloxacin,
while rifabutin increases azithromycin levels and decreases
moxifloxacin levels.122 163
B. Maximise the PK and pharmacodynamic (PD) parameters of
antibiotics to optimise efficacy: The PK/PD indices that cor-
relate with clinical efficacy vary by antimicrobial
agent.122 164 165 To exert maximal activity, drugs such as
aminoglycosides and ethambutol require high peak concen-
trations relative to the pathogen’s minimal inhibitory con-
centration (Cmax/MIC). Ciprofloxacin and rifampin require
a high concentration time or area under the plasma concen-
tration curve measured over 24 h to MIC ratio (AUC0–24/
MIC) and β-lactam agents require as much time as possible
whereby the concentration persists above the infecting
organism’s MIC (%T> MIC). Macrolide agents such as azi-
thromycin have weak concentration-dependent effects and
time effects, but these agents exert their activity through
intracellular activity, tissue penetration and prolonged, per-
sistent effects, due to their long half-life.166
Floto RA, et al. Thorax 2016;71:1–22. doi:10.1136/thoraxjnl-2015-207360 i15
Supplement
C. Overcome CF-related differences in absorption, distribution
and clearance of drugs: Individuals with CF have different
renal and non-renal clearance of several drugs when com-
pared to individuals without CF, due to reduced bioavailabil-
ity, increased volume of distribution and more rapid
clearance. In addition, hepatic disease and diabetes may
further influence drug metabolism and absorption. Several
recent reviews have addressed evidence-based dosing for
various agents used for treatment of pulmonary exacerba-
tions in CF.167–170 While the relevance of the recommended
dosing schedules is unknown for treatment of NTM, it is
possible that individuals with CF would need higher dosages
of mycobacterial drugs.
With the exception of aminoglycosides, the clinical utility of
TDM during treatment for NTM is unknown for individuals
with and without CF due to a lack of rigorous studies, although
some experts have recommended TDM for mycobacterial
agents on a case-by-case basis.165 A recent retrospective study
assessed the PK and pharmacodynamic parameters for 481
patients with disease caused by MAC.122 Peak serum concentra-
tions within reference/normal ranges were only achieved for eth-
ambutol, clarithromycin and azithromycin, in 52%, 44% and
65% of patients, respectively. In addition, pharmacodynamic
targets for Cmax/MIC or AUC0–24/MIC were rarely achieved.
However, these observations were not linked with clinical
outcomes.
Another recent evaluation of the potential utility for TDM in
130 individuals without CF treated for MAC found no associ-
ation between peak plasma/MIC ratios for clarithromycin,
rifampin or ethambutol, and clinical outcomes.171 As previously
observed, rifampin had a substantial impact on clarithromycin
levels; those treated with both drugs had a median peak plasma
clarithromycin concentration of 0.3 mg/mL, while those treated
with rifabutin had a median peak plasma concentration of
1.8 mg/mL, and those with M. abscessus (n=60) treated without
rifampin had a median peak plasma concentration of 3.8 mg/
mL. In all, 97% of patients with MAC treated with daily
therapy and 100% of patients on intermittent therapy reached
the target of 2 mg/mL for clarithromycin. These experts con-
cluded that TDM for treatment of MAC lung disease may not
be beneficial (although the effects of dose optimisation on clin-
ical outcomes were not evaluated).
To the best of our knowledge, there is only one case series,
published over a decade ago, examining the potential role of
TDM in CF. Ten patients with CF with mycobacterial disease
(6 with MAC, 3 with M. abscessus and 1 with M. tuberculosis)
had serum drug concentration measurements performed 2 and
4 h after ingestion.164 Monitoring serum levels at two time
points helped distinguish between poor absorption and delayed
absorption. Half of the patients had inadequate serum levels for
one or more drugs, and one patient clinically improved follow-
ing dose adjustments that achieved target serum levels.
However, target concentrations were not achieved for several
patients. Notably, this study did not compare outcomes in
patients with and without TDM.
Treatment: adjuvant therapy and surgery
In the context of infectious disease, adjuvants have been defined
as ‘therapies that act by rendering the organism more susceptible
to attack by antibiotics or the host immune system, by rendering
the organism less virulent or killing it by other means’.172
A number of approaches have been proposed as candidates for
adjuvant therapy in NTM infection in CF, including interferon
γ (IFNγ; or agents that promote IFNγ release) and vitamin
D. Drug delivery vehicles, such as liposomes, may be considered
adjuvants. Liposomes have been studied as a mode of delivering
amikacin for infection with P. aeruginosa in CF,173 and this
approach is also being evaluated (clinicaltrials.gov/show/
NCT01315236) for NTM.
Does IFNγ therapy improve treatment outcomes in individuals
with CF who have NTM-PD?
Recommendation 42: The CF Foundation and the ECFS recom-
mend against the use of IFNγ as adjuvant therapy for NTM-PD
in individuals with CF.
IFNγ plays a critical role in the host defence against NTM
infection: (1) deficiencies in IFNγ signalling (caused by deleteri-
ous mutations174 or neutralising autoantibodies175) lead to
(usually disseminated) NTM infection in individuals without
CF; (2) inoculation of mice deficient in IFNγ or IFNγ receptors
results in disseminated NTM infection;176 (3) addition of IFNγ
to NTM-infected human macrophages in vitro enhances intra-
cellular killing probably through autophagy stimulation.43
In non-CF individuals, adjuvant IFNγ therapy in NTM infec-
tion has been examined in several studies.177 178 An uncon-
trolled trial of IFNγ was conducted in seven patients with
presumed primary immunodeficiency (three with familial sus-
ceptibility to MAC and four with idiopathic CD4 lymphopae-
nia) who had disseminated NTM disease refractory to
conventional antibiotic therapy.177 All the patients improved
with the introduction of subcutaneous IFNγ two or three times
per week.
In a randomised, placebo controlled trial, 32 patients with
pulmonary NTM disease (30 with MAC) were randomised to
receive either intramuscular IFNγ (1×106 IU) or placebo once
daily for 4 weeks and then three times weekly for 20 weeks178
in addition to daily oral azithromycin, ciprofloxacin, ethambutol
and rifampin. The primary outcome (a composite end point of
improvements in symptoms, radiology and microbiology) was
achieved at 6 months by 72% (13/18) of patients in the IFNγ
arm compared to 36% (5/14) receiving placebo (p=0.037). The
greater response rate with IFNγ was sustained at 12 months
after completion of treatment. However, the small study size,
the use of composite end points and the lack of microbiological
response after 6 months treatment mean that these data need to
be interpreted with caution.
Furthermore three large trials (ClinicalTrials.gov Identifiers
NCT00001318, NCT00111397 and NCT00043355) examin-
ing IFNγ therapy for pulmonary NTM disease remain unpub-
lished or have been terminated (potentially due to lack of
efficacy), again questioning the role of IFNγ adjuvant therapy.
Does vitamin D supplementation improve treatment outcomes in
individuals with CF who have NTM-PD?
Recommendation 43: The CF Foundation and the ECFS recom-
mend that vitamin D should be supplemented according to
national CF care guidelines.
Vitamin D is thought to play a critical role in host defence
against mycobacteria. In vitro and ex vivo treatment with
vitamin D of human macrophages infected with M. tuberculosis
enhances intracellular killing (through stimulating antimicrobial
peptide production179 and autophagy.180) Furthermore, several
epidemiological studies have shown an association of vitamin D
deficiency with reactivation of TB181 182 and, recently, the pres-
ence of NTM-PD.71 However, interventional trials of vitamin D
supplementation in patients with active pulmonary TB have had
mixed results,183 and there are no trials of vitamin D as an adju-
vant treatment for NTM disease.
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Should surgery be considered in individuals with CF who have
NTM-PD?
Recommendation 44: The CF Foundation and the ECFS recom-
mend that lung resection should only be considered under extra-
ordinary circumstances and in consultation with experts on the
treatment of NTM and CF.
Surgical resection has been used extensively in the manage-
ment of pulmonary mycobacterial infection in order to excise
localised infection, debulk severe disease, or excise cavities or
damaged lung into which antibiotic penetration may be
impaired. In no cases has surgery been used as a substitute for
antibiotic therapy. There are no randomised trials of surgery for
the treatment of pulmonary NTM disease in any patient group.
While many publications report the use of lung resection (pneu-
monectomy, lobectomy or segmentectomy) with combination
antibiotic therapy in NTM infection, most are case reports with
no comparator group receiving only medical therapy thereby
preventing objective assessment of the efficacy of surgery.
Nonetheless, three series of individuals without CF do
contain some comparison data although the potential for selec-
tion bias of patients considered suitable for surgery makes inter-
pretation difficult. The first series136 comprised of 65 patients,
from South Korea, with pulmonary M. abscessus infection.
Surgery was performed in 14 patients who failed to achieve
sputum culture conversion, became culture positive again after a
period of culture negativity or experienced disease-related com-
plications such as haemoptysis. Of the eight patients who were
sputum culture positive before surgery, seven became culture
negative postoperatively (compared to culture conversion rates
of 38/65 for the group as a whole). A second study, from the
USA,129 reported outcomes for 69 patients with pulmonary
M. abscessus infection all treated with combination antibiotics,
23 of whom underwent additional surgical resection.
Indications for surgery included the presence of localised bron-
chiectasis, cavitary disease and haemoptysis. In the surgical
group, significantly more patients (13/23) became persistently
sputum culture negative compared to those in the medical treat-
ment only group (13/46). A third study, also from the USA,
described outcomes in 51 patients with macrolide-resistant
MAC-PD.126 Individuals receiving both surgical resection and
injectable aminoglycoside therapy had greater sputum conver-
sion rates (11/14 patients) than those receiving neither treatment
modality (2/37 patients).
A recent review of case series published over the last 40
years184 suggests that localised resection (lobectomy or segmen-
tectomy) should be considered for severe, localised, unilateral
NTM disease that has failed to respond to conventional anti-
biotic therapy. In the context of CF, however, localised NTM
disease is extremely rare (or at least very difficult to identify),
and the risks of thoracic surgery are high and therefore the
potential benefits of surgical resection limited.
TRANSPLANTATION
Should individuals with CF with current or previous
NTM-positive cultures be referred for lung transplantation?
Recommendation 45: The CF Foundation and the ECFS recom-
mend that all individuals with CF being considered for lung
transplantation should be evaluated for NTM-PD.
Recommendation 46: The CF Foundation and the ECFS rec-
ommend that the presence of current or previous respiratory
tract samples positive for NTM should not preclude individuals
being considered for lung transplantation.
Recommendation 47: The CF Foundation and the ECFS rec-
ommend that individuals with CF who have NTM-PD and are
being evaluated for transplantation should start treatment prior
to transplant listing.
Recommendation 48: The CF Foundation and the ECFS rec-
ommend that individuals with CF receiving NTM treatment
with sequential negative cultures may be eligible for transplant
listing.
Recommendation 49: The CF Foundation and the ECFS rec-
ommend that individuals with CF who have completed treat-
ment for NTM-PD with apparent eradication of the organism
may be eligible for transplant listing.
Recommendation 50: The CF Foundation and the ECFS rec-
ommend that the presence of persistent MABSC or MAC infec-
tion despite optimal therapy is not an absolute contraindication
to lung transplant referral.
The International Society for Heart and Lung Transplantation
(ISHLT) International Guidelines lists ‘colonisation with highly
resistant or virulent mycobacteria’ as a relative contra-indication
for selection as a lung transplant candidate.185 There is,
however, limited published information on transplant outcomes
for individuals with previous or concurrent NTM infection,
with very few reports (usually from single centres) specifically
examining CF cohorts.186 187
The risk of NTM infection post-transplantation is not well
defined. A study of 201 CF and non-CF transplant recipients188
suggested that postoperative NTM acquisition was associated
with increased mortality (HR 2.61), independent of bronchio-
litis obliterans syndrome. However, these data should be inter-
preted keeping the following in mind: very little data were
available on the presence of pulmonary NTM pretransplant; the
vast majority of patients did not have CF or even bronchiectasis;
and non-NTM-related causes were major contributors to death
in fatal cases. In contrast, a recent study of CF and non-CF
transplant recipients189 reported that 53 of 237 individuals
(22.4%) acquired NTM-positive cultures postoperatively (70%
MAC, 10% MABSC), of whom two fulfilled ATS/IDSA criteria
for NTM-PD. Although overall mortality was not affected by
NTM acquisition, four patients developed persistent surgical
site infection (three with M. abscessus), of whom one died of
disseminated NTM infection. The potential for M. abscessus to
cause significant postoperative complications is supported by a
review of outcomes from 31 transplant centres190 indicating fre-
quent soft tissue and surgical site infections, and two deaths,
attributable to M. abscessus infection.
The largest CF-specific case series comes from the University
of North Carolina Chapel Hill experience between 1990 and
2003.29 One hundred and forty-six patients with CF underwent
lung transplantation and 31 listed for transplantation. Of those
individuals referred, 19.7% were NTM culture positive pre-
transplant. Rates of NTM following lung transplantation were
3.4%. Pretransplant infection with M. abscessus was recognised
as a significant risk factor for recurrence of NTM post-
transplantation. Although there was no effect on mortality, post-
transplant NTM infection caused significant morbidity as
patients developed M. abscessus-associated skin and soft tissue
infection or pulmonary disease caused by MAC and other NTM
species. There are several published case series of successful out-
comes for individuals with CF who have culture positive
M. abscessus infection at the time of transplantation.186
However, NTM-related complications in this group may be
more frequent, and include persistent soft tissue or wound
infections,186 empyema and disseminated NTM infection.164 191
Although a small series, the University of North Carolina
(UNC) report suggests no effect of the presence of pretransplant
M. abscessus positive cultures on post-transplant mortality.187
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The Consensus statements Committee concluded that all indi-
viduals with CF should be evaluated for NTM disease prior to
referral for lung transplantation, given the very high reported
rates of NTM culture positivity for this group, and the fact that
untreated NTM infection may represent an increased (and
potentially modifiable) postoperative risk. Consequently, if
NTM-PD is diagnosed, treatment should be started prior to
transplant listing.
CONCLUSION
The management of individuals with CF infected with NTM is
extremely challenging. The limited amounts of published
research and clinical trial data provide inadequate evidence to
base management decisions on how best to screen, diagnose,
detect and treat NTM-PD. As a response to this urgent clinical
need, the CF Foundation and the ECFS formed a committee of
clinicians, scientists and infectious disease experts to develop
recommendations to guide and assist clinicians in the manage-
ment of NTM-PD in individuals with CF. The committee
believes these recommendations should serve as a benchmark
for current medical care while providing a framework to inform
the development of clinical, translation and basic research
studies to generate robust evidence on which to base future
iterations of these management guidelines, leading to better out-
comes for individuals with CF infected with NTM.
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